Our follow-up analyses of GWAS showed that DOCK2-mediated signalling has a key role in the response to SARS-CoV-2 infection, suggesting that the hypomorphic DOCK2 allele is involved in exacerbation of COVID-19 pathology, and that DOCK2 could serve as a potential clinical biomarker to predict severe COVID-19. The gene discussed is DOCK2; the disease is COVID-19.